Darovasertib NDA progress backed by a massive cash runway
- IDEAYA has no approved products and no product sales today.
- Darovasertib is the lead drug, with positive pivotal data in uveal melanoma.
- The company is pre-submitting an NDA using the FDA Real-Time Oncology Review program.
- Cash and marketable securities jumped to $1.24 billion after a June 2026 public offering.
- The bear case centers on FDA review risks and the challenge of building a commercial launch team.
Regulatory action and fresh funding
IDEAYA is moving its lead asset through the final regulatory steps. In the second quarter of 2026, the company began pre-submitting pieces of its New Drug Application for darovasertib under the FDA Real-Time Oncology Review program. This program is designed to speed up the review of cancer treatments with strong clinical data.
The financial picture is stronger than ever. A June 2026 stock offering brought in about $345 million in gross proceeds. That puts the total cash balance at $1.24 billion, effectively removing any short-term funding fears for a company with no product revenue.
The bull case is straightforward. Darovasertib has a clear path to potential approval, and the massive cash balance pays for the launch while funding the rest of the clinical pipeline. That pipeline continues to expand, highlighted by a new clinical supply agreement with Roche for IDE892.
The bear case remains tied to execution. IDEAYA has never launched a drug before. The FDA could still reject the filing, ask for more safety data, or delay the timeline. Building a U.S. sales force will also burn significant capital before any revenue arrives.
Paid by partners, not patients
IDEAYA does not sell medicine yet. Its revenue has come from collaboration deals, mainly with Servier and historically with GSK. These deals can include upfront cash, milestone payments, and royalties if drugs reach the market.
The August 2025 Servier deal gave IDEAYA $210 million upfront and potential future milestones of up to $320 million, plus double-digit royalties on net sales outside the United States. IDEAYA kept the U.S. opportunity for darovasertib, which will be critical if the drug wins FDA approval.
The model depends entirely on clinical success. If trials fail or regulators say no, the company has no fallback revenue source. The wide pipeline also means research spending will stay high as more programs enter larger and more expensive trials.
Four focus areas, one lead asset
Darovasertib for uveal melanoma
This is the most advanced program. It is being tested in metastatic, neoadjuvant, and adjuvant uveal melanoma, a rare eye cancer often linked to GNAQ and GNA11 mutations.
IDE849, DLL3 antibody drug conjugate
IDE849 is aimed at DLL3-positive solid tumors, including small cell lung cancer and neuroendocrine tumors.
IDE161, PARG inhibitor
IDE161 is part of the DNA damage response strategy. The idea is to attack cancers that depend on certain repair pathways to survive.
IDE397, MAT2A inhibitor
IDE397 targets tumors with MTAP deletion. This is a selected cancer group, which fits the plan to match drugs to tumor biology.
IDE892, PRMT5 inhibitor
IDE892 is an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP gene deletion. A combination trial with a Roche drug is planned.
IDE034 and IDE574
IDE034 is a bispecific antibody drug conjugate, and IDE574 is a dual inhibitor. Both add future upside but are less proven than darovasertib.
One research business
IDEAYA reports as one operating segment focused on targeted cancer drug discovery and development. For Q2 2026, the company had no commercial products, meaning product sales were 0%.
What could break
FDA says the package is not enough
High impact · Medium oddsDarovasertib is not approved. Even with the Real-Time Oncology Review process, the FDA could ask for longer follow-up or more safety data. That would push out the first possible product revenue.
First launch is harder than expected
High impact · Medium oddsIDEAYA has no prior commercial launch record. Even a good rare cancer drug needs doctors to test the right patients, payers to cover it, and a sales team that can reach specialist centers.
Cash burn rises with the pipeline
Medium impact · High oddsThe company had $1.24 billion in cash and marketable securities at June 30, 2026. Still, later-stage trials cost more, and IDEAYA is advancing multiple programs at once. The burn rate will increase.
Supply chain or policy shock
Medium impact · Medium oddsThe company has flagged U.S. policy risks. The BIOSECURE Act could limit use of certain foreign contract manufacturers. Separately, Medicaid funding cuts could hurt future sales if an approved drug depends on that payer base.
In one breath
Does IDEAYA Biosciences have any approved drugs?
No. IDEAYA has no approved products and no product sales. Its most advanced drug is darovasertib, which the company is currently submitting to the FDA.
What is darovasertib used for?
Darovasertib is being developed for uveal melanoma, a rare cancer that starts in the eye and can spread to the liver and other organs.
How does IDEAYA make money today?
IDEAYA makes money from collaboration and license agreements, not drug sales. The Servier deal for darovasertib outside the United States included a $210 million upfront payment.
What is the main thing to watch next?
The key watch item is the FDA review process for darovasertib. Investors should also watch how quickly IDEAYA builds a U.S. launch team.
